Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erlotinib + seribantumab
- Development stage
- Unknown
- Lead developer
- Elevation Oncology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Erlotinib + seribantumab is a combination therapy evaluated primarily in advanced non-small cell lung cancer (NSCLC), especially in patients with EGFR wild-type tumors. Erlotinib is a small molecule tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR), while seribantumab (MM-121) is a fully human IgG2 monoclonal antibody that binds to human epidermal growth factor receptor 3 (HER3/ErbB3). Seribantumab blocks heregulin (HRG/NRG)-mediated ErbB3 signaling and induces receptor downregulation. The combination was studied for its potential to improve outcomes by dual inhibition of EGFR and HER3 pathways, particularly in biomarker-selected populations with detectable HRG mRNA expression[1][2][5].
- Other names
- seribantumab plus erlotinib
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on erlotinib + seribantumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erlotinib + seribantumab.